| First Author | Gibbons DL | Year | 2014 |
| Journal | Cancer Discov | Volume | 4 |
| Issue | 9 | Pages | 991-4 |
| PubMed ID | 25185188 | Mgi Jnum | J:217914 |
| Mgi Id | MGI:5616048 | Doi | 10.1158/2159-8290.CD-14-0791 |
| Citation | Gibbons DL, et al. (2014) A HER 1-2 punch: dual EGFR targeting deals resistance a deadly blow. Cancer Discov 4(9):991-4 |
| abstractText | SUMMARY: Ten years after the approval of erlotinib, EGFR inhibitor resistance remains a major clinical challenge. The translation of afatinib plus cetuximab into the clinic provides a promising new option for the treatment of patients with EGFR-mutated lung cancer. |
